Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients

Bayer

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Drug: Interferon beta-1b, (Betaseron BAY86-5046)

Study type: Observational

Funder types: Industry

Identifiers

NCT00928967

Daily Life Study (Other Identifier)

BF0610FR (Other Identifier)

14168

Details and patient eligibility

About

To evaluate the evolution of the impact on daily life activities over the first 12 months following the introduction of interferon beta-1b treatment in patients presenting RRMS or patients at high risk of developing Multiple Sclerosis after a first clinical demyelinating event

Enrollment: 67 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Males or females aged 18 years or over, having received a confirmed diagnosis of RRMS as defined by the MacDonald or Poser criteria or after a first clinical demyelinating event suggestive of Multiple Sclerosis, and meeting the requirements of the study inclusion criteria
• The choice of treatment must be clearly dissociated from the decision to include the patient in the study.

Trial design

67 participants in 1 patient group

Group 1

Treatment:

Drug: Interferon beta-1b, (Betaseron BAY86-5046)